Jong Ho Cho
성균관대학교 의과대학 · 의학
Jong Ho Cho 교수의 연구실은 주로 폐암 및 흉부외과 영역에서의 정밀의료와 수술적 치료 전략 개발에 중점을 두고 있습니다. 특히 결절성 폐암 환자에서의 다발성 폐전이에 대한 수술적 접근, EGFR 돌연변이를 가진 비소세포폐암 환자의 예후 생존과 PD-L1 발현 간의 연관성, 만성 폐질환 환자에서의 비삽입식 VATS 생검의 안전성 등 첨단 흉부외과 수술 기법과 예후 예측 요법을 연구하고 있습니다. 환자 중심의 개인화된 치료 전략 수립을 위한 임상 기반의 연구가 핵심입니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
The overall survival and recurrence after pulmonary metastasectomy for CRC is dependent on the number of metastases. Surgical treatment can be offered to patients with three or fewer pulmonary metastases. However, more meticulous patient selection is required to decide whether a surgical approach is feasible in patients with four or more pulmonary metastases.
We identified previous chemotherapy or radiotherapy and poor performance status (ECOG 3 or 4) as significant predictors of OS after VATS talc pleurodesis. These prognostic factors can help surgeons select candidates for VATS pleurodesis for malignant pleural effusion.
PD-L1 expression is associated with disease stage and type of <i>EGFR</i> mutation. PD-L1 positivity might be associated with worse RFS among patients with surgically treated <i>EGFR</i>-mutant NSCLC.
These preliminary results suggest that non-intubated VATS lung biopsy is a safe and feasible option in patients with ILD.
Conditional survival estimates generally increase over time, and the largest improvements were observed for patients with advanced stage. Availability of updated prognosis at various time points allows clinicians to better guide their patients. Our results also imply substantial residual risk of recurrence and sustained excess mortality compared to the general population even after 5 years.
Repositioning of the mediastinum with placement of a saline filled tissue expander for PPS is very effective for the relief of symptoms, with low mortality.
Our findings suggest that individuals with MetS may be at increased risk for esophageal cancer, specifically ESCC. Further studies are needed to establish the relationship between MetS and esophageal cancer.
Bilobectomy is associated with high operative mortality and poor long-term survival after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer. The outcomes of bilobectomy were similar to those of pneumonectomy in terms of overall survival, disease-free survival, and postoperative mortality.
